Related Experiment Videos
Phenotypic reversion induced by anthracyclines in ras oncogene-expressed cells; structure-activity relationships
T Kanbe1, K S Tsuchiya, M Hori
1Showa College of Pharmaceutical Sciences, Tokyo, Japan.
Biological & Pharmaceutical Bulletin
|April 1, 1994
Summary
Anthracyclines can reverse tumor cell characteristics. Pirarubicin showed greater anti-ras activity than aclarubicin in preclinical models, suggesting structural differences influence efficacy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Ras oncogenes drive tumor development by altering cell phenotypes.
- Anthracyclines are a class of antitumor antibiotics with diverse mechanisms.
- Understanding structure-activity relationships is crucial for drug development.
Purpose of the Study:
- To investigate the anti-ras activity of various anthracyclines.
- To correlate anthracycline chemical structure with phenotypic reversion of ras-transformed cells.
- To evaluate anthracycline efficacy in preclinical tumor models.
Main Methods:
- Utilized H- or K-ras transformed NIH3T3 cells to assess phenotypic reversion.
- Tested anthracyclines for their ability to restore normal cell morphology and growth dependence.
- Employed a nude mouse xenograft model with K-ras 3T3 solid tumors to compare pirarubicin and aclarubicin efficacy.
Main Results:
- Several anthracyclines demonstrated the ability to reverse tumorous phenotypes in ras-transformed cells.
- A correlation between anthracycline chemical structure and anti-ras activity was identified.
- Pirarubicin exhibited over fourfold greater efficacy than aclarubicin in inhibiting K-ras 3T3 solid tumor growth in vivo.
Conclusions:
- Anthracyclines possess anti-ras activity, capable of reverting oncogenic phenotypes.
- Chemical structure significantly influences the anti-ras efficacy of anthracyclines.
- Pirarubicin represents a promising candidate for further investigation due to its superior preclinical anti-ras activity.